|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2000-4-27
|
|
pubmed:abstractText |
Second-line chemotherapy for patients with nonsmall cell lung carcinoma has been ineffective due to the lack of activity of older agents following platinum-based therapy. This Phase II trial evaluated the feasibility, toxicity, and efficacy of two active new agents, gemcitabine and vinorelbine, used in combination as second-line therapy for patients with nonsmall cell lung carcinoma.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antimetabolites, Antineoplastic,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Phytogenic,
http://linkedlifedata.com/resource/pubmed/chemical/Bridged Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/Deoxycytidine,
http://linkedlifedata.com/resource/pubmed/chemical/Platinum Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/Taxoids,
http://linkedlifedata.com/resource/pubmed/chemical/Vinblastine,
http://linkedlifedata.com/resource/pubmed/chemical/gemcitabine,
http://linkedlifedata.com/resource/pubmed/chemical/taxane,
http://linkedlifedata.com/resource/pubmed/chemical/vinorelbine
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2000 American Cancer Society.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
88
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1353-8
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:10717616-Actuarial Analysis,
pubmed-meshheading:10717616-Adult,
pubmed-meshheading:10717616-Aged,
pubmed-meshheading:10717616-Antimetabolites, Antineoplastic,
pubmed-meshheading:10717616-Antineoplastic Agents,
pubmed-meshheading:10717616-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:10717616-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:10717616-Bridged Compounds,
pubmed-meshheading:10717616-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:10717616-Deoxycytidine,
pubmed-meshheading:10717616-Disease Progression,
pubmed-meshheading:10717616-Feasibility Studies,
pubmed-meshheading:10717616-Female,
pubmed-meshheading:10717616-Fever,
pubmed-meshheading:10717616-Humans,
pubmed-meshheading:10717616-Lung Neoplasms,
pubmed-meshheading:10717616-Male,
pubmed-meshheading:10717616-Middle Aged,
pubmed-meshheading:10717616-Neutropenia,
pubmed-meshheading:10717616-Platinum Compounds,
pubmed-meshheading:10717616-Remission Induction,
pubmed-meshheading:10717616-Survival Rate,
pubmed-meshheading:10717616-Taxoids,
pubmed-meshheading:10717616-Thrombocytopenia,
pubmed-meshheading:10717616-Vinblastine
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Gemcitabine and vinorelbine in the second-line treatment of nonsmall cell lung carcinoma patients: a minnie pearl cancer research network phase II trial.
|
|
pubmed:affiliation |
Sarah Cannon Cancer Center, Nashville, Tennessee 37203, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
